

해외 바이오의약품 임상 현황 ('23년 6월 3주)

한국바이오의약품협회, 2023.06.27.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

모니터링 기간: 2023.06.19.~2023.06.25.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 11건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05672459	A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors	Drug: Single Injection of IVS-3001- Anti - HLA-G CAR-T cells Drug: Fludarabine phosphate Drug: Cyclophosphamide Procedure: leukapheresis	M.D. Anderson Cancer Center Invectys	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05672459&rank=1
NCT05911997	MTC Versus FMT in for RCDI	Drug: MTC 01 Drug: Fecal Microbiota Transplantation (FMT)	Icahn School of Medicine at Mount Sinai National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05911997&rank=1
NCT05903274	JSP191 (Briquilimab) in Subjects With LR-MDS	Drug: JSP191	Jasper Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05903274&rank=1
NCT05901883	First-in-human, Single Ascending Dose Study of CEL383 in Healthy Adult Subjects	Drug: CEL383 Drug: Placebo	Celsius Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05901883&rank=1
NCT05445609	Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer	Drug: VLP-encapsulated TLR9 Agonist CMP-001, Biological: Nivolumab	Emory University National Cancer Institute (NCI) Prostate Cancer Foundation	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05445609&rank=1
NCT05127824	Autologous Dendritic Cell Vaccine in Kidney Cancer	Biological: Autologous alpha-DC1/TBVA vaccine Drug: Cabozantinib	Jodi Maranchie University of Pittsburgh	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05127824&rank=1
NCT04054752	Vaccine Response With NT-I7	Biological: Recombinant human IL-7-hyFc (NT-I7) Biological: Vaccine sequence 1 Biological: Vaccine sequence 2	National Cancer Institute (NCI) NeolImmuneTech, Inc. National Institutes of Health Clinical Center (CC)	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT04054752&rank=1
NCT05724472	Evaluation of Safety and Immunogenicity of rVSV?G-SEBOV-GP Vaccine in Adults With Good General Health	Drug: rVSVΔG-SEBOV-GP Vaccine or Placebo	International AIDS Vaccine Initiative Biomedical Advanced Research and Development Authority	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05724472&rank=1
NCT05568550	Pembro With Radiation With or Without Olaparib	Biological: Pembrolizumab Drug: Olaparib Drug: Androgen Deprivation Therapy Radiation: Radiation Therapy	Zin W Myint Merck Sharp & Dohme LLC University of Kentucky	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05568550&rank=1
NCT05919069	A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693	Drug: AZD2693	AstraZeneca	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT05919069&rank=1
NCT05722938	Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)	Drug: Trimodulin Drug: Placebo (human albumin 1%)	Biotest	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05722938&rank=1

해외 바이오의약품 임상 현황 ('23년 6월 3주)

한국바이오의약품협회, 2023.06.27.

○ 중국 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05915481	Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors	Drug: Cadonilimab Radiation: Stereotactic body radiotherapy	Peking University Third Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05915481
NCT05913570	Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer	Drug: Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody	LiuYing Henan Cancer Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05913570
NCT05910970	Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation	Drug: Adjuvant tislelizumab plus lenvatinib Drug: Adjuvant tislelizumab	Guangxi Medical University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05910970

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05914155	Phase III Study of Rituximab (Genetical Recombination) for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome	Drug: Rituximab (genetical recombination) Drug: Placebo	Shoichi Maruyama MD PhD Nagoya University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05914155